

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

34

Application Number

10/516,505

Filing Date

12-01-2004

First Named Inventor

C. Frank Bennett

Art Unit

Examiner Name

Attorney Docket Number

PTS-0055 USA

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Statement under 3.73(b)	

table

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Isis Pharmaceuticals, Inc.		
Signature			
Printed name	Donna T. Ward, Ph.D.		
Date	9/30/05	Reg. No.	48,271


### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Pamela Grooms	Date	9-30-2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	See Attached Table
Filing Date	See Attached Table
First Named Inventor	See Attached Table
Art Unit	
Examiner Name	
Attorney Docket Number	See Attached Table

**I hereby revoke all previous powers of attorney given in the above-identified application.**

☐ A Power of Attorney is submitted herewith.

**OR**

☒ I hereby appoint the practitioners associated with the Customer Number:

34,138

☐ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
Customer Number:

34,138

**OR**

<input type="checkbox"/> Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone			Fax		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**


Signature			
Name	Grantland E. Bryce, Esq.		
Date	09/29/2005	Telephone	760 931-9200

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Isis Pharmaceuticals, IncApplication No./Patent No.: See Attached Table Filed/Issue Date: See Attached TableEntitled: See Attached TableIsis Pharmaceuticals, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel See Attached Table, Frame See Attached Table, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

09/29/2005

Date

Grantland E. Bryce, Esq.

Printed or Typed Name

760 931-9200

Telephone Number

Vice President and General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Table A	Serial Number	Filing Date	Title	Reel	Frame	Inventor	Docket Number	New Customer Number
	60/620,792	10/20/2004	AEROSOL DELIVERY OF VLA-4 SPECIFIC ANTISENSE OLIGONUCLEOTIDES INHIBIT AIRWAY INFLAMMATION AND HYPERRESPONSIVENESS IN MICE	15825	819	Bennett, C. Frank	BIOL0049US.L	27,180
	60/648,820	01/31/2005	AEROSOL DELIVERY OF VLA-4 SPECIFIC ANTISENSE OLIGONUCLEOTIDES INHIBIT AIRWAY INFLAMMATION AND HYPERRESPONSIVENESS IN MICE	15987	402	Bennett, C. Frank	BIOL0049US.L2	27,180
	60/667,581	04/01/2005	COMPOSITIONS AND THEIR USES DIRECTED TO INTEGRIN ALPHA 5	16248	879	Bennett, C. Frank	BIOL0054US.L	27,180
	09/915,814	07/26/2001	ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION	12429	605	Butler, Madeline M.	ISPH-0587	34,138
	10/006,191	12/10/2001	ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION	13694	583	Gaarde, William A.	RTS-0274	34,138
	10/111,868	08/06/2002	ANTISENSE MODULATION OF RANK EXPRESSION	13797	278	Baker, Brenda F.	RTSP-0313	34,138
	10/111,868	08/06/2002	ANTISENSE MODULATION OF RANK EXPRESSION	14401	109	Baker, Brenda F.	RTSP-0313	34,138
	10/159,856	05/31/2002	ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRESSION	12974	419	Freier, Susan M.	RTS-0365	34,138
	10/274,085	10/17/2002	ANTISENSE MODULATION OF FATTY ACID SYNTHASE EXPRESSION	13795	879	Freier, Susan M.	ISPH-0714	34,138
	10/516,505	12/01/2004	ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 EXPRESSION	16444	934	Bennett, C. Frank	PTS-0055USA	34,138
	10/754,415	01/09/2004	A SECONDARY STRUCTURE DEFINING DATABASE AND METHODS FOR DETERMINING IDENTITY AND GEOGRAPHIC ORIGIN OF AN UNKNOWN BIOAGENT THEREBY	15473	192	Ecker, David J.	DIBIS-0003US.P2	34,138
	10/880,427	06/28/2004	A METHOD FOR SELECTING AN ACTIVE OLIGONUCLEOTIDE PREDICTIVE MODEL	15262	234	Sipes, Tamara Balac	CORE0002US	34,138
	10/944,274	09/17/2004	MODULATION OF RANKL EXPRESSION	15820	665	Baker, Brenda F.	RTS-0618US	34,138